02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
22:43 , May 15, 2019 |  BC Extra  |  Company News

May 15 Company Quick Takes: Approvals for Bavencio in RCC, Venclexta-Gazyva combo; plus Adaptimmune, Alpine, Advaxis

Bavencio gets RCC approval with Inlyta  FDA approved Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) for first-line treatment of advanced renal cell carcinoma in combination with Pfizer's Inlyta axitinib, making Bavencio the...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
20:35 , Apr 21, 2017 |  BC Week In Review  |  Company News

Alpine, Nivalis deal

Immunology company Alpine will reverse-merge cystic fibrosis play Nivalis in a stock deal. The combined entity will retain Alpine’s name and will trade on NASDAQ under a new ticker. Alpine’s current CEO, Mitchell Gold, will...
23:24 , Apr 18, 2017 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...
07:00 , Sep 16, 2016 |  BC Extra  |  Company News

Management tracks

EMA said Head of International Affairs Emer Cooke will leave the agency to join the World Health Organization as head of regulation of medicines and other health technologies in WHO's essential medicines and health products...
07:00 , Jun 20, 2016 |  BioCentury  |  Finance

Mountain of cash

Investors in Alpine Immune Sciences Inc. decided the company's A round had to get the preclinical immunotherapy company to human efficacy data. The syndicate therefore is pouring in $48 million, about double the average size...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Alpine Immune Sciences completes venture financing

Alpine Immune Sciences Inc. , Seattle, Wash.   Business: Cancer, Autoimmune, Infectious   Date completed: 2016-06-13   Type: Venture financing   Raised: $48 million   Investors: OrbiMed Advisors; Frazier & Co.; Alpine BioVentures  ...